We are live on ! Find out more
PR

PSP Research Portfolio holdings

AUM $188M
This Fund
S&P 500
This Quarter Est. Return
+18.09%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
–
Cap. Flow
+$110M
Cap. Flow %
96.55%
Top 10 Hldgs %
65.84%
Holding
85
New
85
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 quarters
Top 10 Avg Time Held
0 quarters
Top 20 Avg Time Held
0 quarters

Top Buys

Rank Stock Value
1
SGOV icon
iShares 0-3 Month Treasury Bond ETF
SGOV
+$70.3M
2
LEGN icon
Legend Biotech
LEGN
+$699K
3
ACLX
Arcellx
ACLX
+$656K
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$601K
5
MLYS icon
Mineralys Therapeutics
MLYS
+$594K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Miscellaneous 61.41%
2 Healthcare 38.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SGOV icon
1
iShares 0-3 Month Treasury Bond ETF
SGOV
$112B
$70.3M 61.41%
+700,000
New +$70.3M
2025 Q4
0 quarters
PRAX icon
2
Praxis Precision Medicines
PRAX
$7.26B
$584K 0.51%
+1,982
New +$369K
2025 Q4
0 quarters
TVTX icon
3
Travere Therapeutics
TVTX
$4.91B
$584K 0.51%
+15,272
New +$497K
2025 Q4
0 quarters
TYRA icon
4
Tyra Biosciences
TYRA
$1.37B
$575K 0.5%
+21,853
New +$401K
2025 Q4
0 quarters
PHVS icon
5
Pharvaris
PHVS
$2.18B
$569K 0.5%
+20,511
New +$494K
2025 Q4
0 quarters
JAZZ icon
6
Jazz Pharmaceuticals
JAZZ
$14.2B
$554K 0.48%
+3,258
New +$499K
2025 Q4
0 quarters
CLDX icon
7
Celldex Therapeutics
CLDX
$2.35B
$553K 0.48%
+20,368
New +$536K
2025 Q4
0 quarters
CGON icon
8
CG Oncology
CGON
$5.66B
$552K 0.48%
+13,293
New +$550K
2025 Q4
0 quarters
BLTE
9
Belite Bio
BLTE
$6.22B
$551K 0.48%
+3,443
New +$408K
2025 Q4
0 quarters
ASND icon
10
Ascendis Pharma A/S
ASND
$15.1B
$550K 0.48%
+2,579
New +$533K
2025 Q4
0 quarters
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$549K 0.48%
+21,866
New +$513K
2025 Q4
0 quarters
TERN
12
DELISTED
Terns Pharmaceuticals
TERN
$548K 0.48%
+13,560
New +$313K
2025 Q4
0 quarters
RVMD icon
13
Revolution Medicines
RVMD
$40.7B
$547K 0.48%
+6,872
New +$451K
2025 Q4
0 quarters
CNTA
14
DELISTED
Centessa Pharmaceuticals
CNTA
$547K 0.48%
+21,879
New +$554K
2025 Q4
0 quarters
BBIO icon
15
BridgeBio Pharma
BBIO
$12.8B
$546K 0.48%
+7,140
New +$469K
2025 Q4
0 quarters
NRIX icon
16
Nurix Therapeutics
NRIX
$2.32B
$545K 0.48%
+28,713
New +$412K
2025 Q4
0 quarters
ARQT icon
17
Arcutis Biotherapeutics
ARQT
$3.34B
$544K 0.48%
+18,716
New +$479K
2025 Q4
0 quarters
KOD icon
18
Kodiak Sciences
KOD
$6.28B
$543K 0.47%
+19,418
New +$398K
2025 Q4
0 quarters
IMNM icon
19
Immunome
IMNM
$2.31B
$542K 0.47%
+25,245
New +$443K
2025 Q4
0 quarters
AUPH icon
20
Aurinia Pharmaceuticals
AUPH
$2.22B
$542K 0.47%
+33,953
New +$481K
2025 Q4
0 quarters
MIRM icon
21
Mirum Pharmaceuticals
MIRM
$5.58B
$541K 0.47%
+6,854
New +$492K
2025 Q4
0 quarters
HALO icon
22
Halozyme
HALO
$12.5B
$540K 0.47%
+8,026
New +$540K
2025 Q4
0 quarters
EYPT icon
23
EyePoint Inc
EYPT
$293M
$540K 0.47%
+29,530
New +$418K
2025 Q4
0 quarters
ALKS icon
24
Alkermes
ALKS
$6.81B
$539K 0.47%
+19,280
New +$577K
2025 Q4
0 quarters
IONS icon
25
Ionis Pharmaceuticals
IONS
$7.52B
$538K 0.47%
+6,800
New +$512K
2025 Q4
0 quarters
1
2 3 4

Similar funds

IJWM
Inman Jager Wealth Management Hattiesburg, Mississippi $188M AUM 19.49% 1-Year Est. Return
TCPG
Trivant Custom Portfolio Group San Diego, California $188M AUM 23.55% 1-Year Est. Return
KCPT
Kingstone Capital Partners Texas Frisco, Texas $188M AUM 26.67% 1-Year Est. Return
DWS
Dynamic Wealth Strategies Granite Bay, California $188M AUM 18.55% 1-Year Est. Return
RMSCM
R.M. Sincerbeaux Capital Management New York $188M AUM 12.59% 1-Year Est. Return
AWP
Astra Wealth Partners Jersey City, New Jersey $188M AUM 26.79% 1-Year Est. Return
NCPF
Nordflint Capital Partners Fondsmaeglerselskab Copenhagen O, Denmark $188M AUM 64.25% 1-Year Est. Return
CFP
Comprehensive Financial Planning East Petersburg, Pennsylvania $188M AUM 48.26% 1-Year Est. Return

PSP Research's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for PSP Research, which disclosed 85 positions worth $114M. Its ten largest holdings account for 66% of the portfolio.

Its largest position is iShares 0-3 Month Treasury Bond ETF: 700,000 shares worth $70.3M.

By sector, the portfolio is most concentrated in Miscellaneous at 61% of assets, followed by Healthcare.

  • PSP Research's largest Q4 2025 buy was iShares 0-3 Month Treasury Bond ETF: 700,000 shares worth $70.3M.
  • PSP Research's ten largest holdings make up 66% of its $114M portfolio in Q4 2025.
  • PSP Research disclosed 85 positions in Q4 2025, its first 13F filing on record.

Based on PSP Research's 13F filing for Q4 2025, filed 6 Feb 2026.